Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 82 от 100

Активно (без набиране) Фаза 1

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

Breast Neoplasm Female

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that venetoclax may augment the actions of palbociclib and letrozole in these patient groups. The primary objective of the study is to determine the maximum tolerated dose of the combination treatment, which can be used in subsequent studies. The study will also investigate disease response and survival. Participants will receive palbociclib (daily, on days 1-21 of each 28 day cycle), letrozole (daily, on days 1-28 of each 28 day cycle) and venetoclax (daily, on days 1-21 of each 28 day cycle) until the last patient has completed 18 months treatment on the study.

Начало: 25.09.2019 Край: 01.12.2025 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT03900884

Активно (без набиране) Фаза 3

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer

The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase.

Начало: 11.09.2019 Край: 31.12.2028 Възраст: от 18 г.

China Astellas Pharma China, Inc. NCT04076059

Активно (без набиране) Фаза 2

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 Anatomic Stage IA Breast Cancer AJCC v8 Anatomic Stage IB Breast Cancer AJCC v8 Anatomic Stage II Breast Cancer AJCC v8 +17

This phase II trial studies whether a prior germline predictor of taxane-induced peripheral neuropathy (TIPN) can help identify a subgroup of patients who are at higher risk of chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. The study also investigates whether docetaxel maybe work better than paclitaxel with regard to TIPN rate/severity and dose reductions.

Начало: 09.08.2019 Край: 31.03.2027 Възраст: от 18 г.

United States ECOG-ACRIN Cancer Research Group NCT04001829

Активно (без набиране) Фаза 3

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.

Начало: 05.08.2019 Край: 10.06.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +19 Bristol-Myers Squibb NCT04008030

Активно (без набиране) Фаза 3

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage III

This phase III trial studies how well axillary reverse mapping works in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast so as to prevent lymphedema after surgery.

Начало: 29.07.2019 Край: 01.01.2027 Възраст: от 18 г.

United States Alliance for Clinical Trials in Oncology NCT03927027

Активно (без набиране) Фаза 3

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

Urinary Bladder Cancer, Muscle-invasive

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone. With Amendment 5, outcome measures for programmed cell death ligand 1 (PD-L1) combined positive score (CPS) were removed. With Amendment 8, the primary outcome measure of pathologic complete response (pCR) rates was changed to a secondary outcome measure.

Начало: 24.07.2019 Край: 15.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Merck Sharp & Dohme LLC NCT03924895

Активно (без набиране) Фаза 1

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).

Начало: 09.07.2019 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT03874884

Активно (без набиране) Фаза 1/2

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Non-Small Cell Lung Cancer

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.

Начало: 09.07.2019 Край: 01.12.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +10 Dizal Pharmaceuticals NCT03974022

Активно (без набиране) Фаза 3

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Prostatic Neoplasms

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.

Начало: 11.06.2019 Край: 13.10.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +15 Janssen Research & Development, LLC NCT03767244

Активно (без набиране) Фаза 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma Locally Advanced Pancreatic Cancer Locally Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm +9

This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial carcinoma, all pancreatic cancers, endometrial cancer, and other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib or durvalumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib or durvalumab may work better in treating participants with solid tumors.

Начало: 17.01.2019 Край: 31.03.2028 Възраст: от 18 г.

United States Rahul Aggarwal NCT03682289

Активно (без набиране)

Cancer Activity and Lifestyle Measurement Study

Breast Cancer

The CALM Study is an observational study to investigate the associations of linoleic acid levels in the blood, diet, activity, and lifestyle factors with measures of muscle strength, muscle function and overall outcomes for postmenopausal breast cancer patients treated with anthracycline chemotherapy.

Начало: 04.01.2019 Край: 01.12.2026 Възраст: 25–70 г.

United States Ohio State University NCT03961685

Активно (без набиране) Фаза 3

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Breast Cancer

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by pathological Complete Response (pCR) rate defined by the local pathologist, and 2) pembrolizumab is superior to placebo (both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies) as assessed by Event-Free Survival (EFS) as determined by the investigator. The study is considered to have met its primary objective if pembrolizumab is superior to placebo with respect to either pCR (ypT0/Tis ypN0) or EFS.

Начало: 27.12.2018 Край: 24.01.2031 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +19 Merck Sharp & Dohme LLC NCT03725059

Активно (без набиране)

Span-C-SBRT for Pancreatic Cancer

High Risk Localised Pancreatic Cancer

To assess the freedom from local failure at 12 months after Stereotactic Body Radiotherapy (SBRT). Also to assess the safety, efficacy and feasibility of SBRT in the treatment of high risk localised pancreatic cancer.

Начало: 18.12.2018 Край: 05.10.2028 Възраст: 18–86 г. Лечение

Australia Royal North Shore Hospital NCT03505229

Активно (без набиране) Фаза 2

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Advanced Solid Neoplasms

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Начало: 12.12.2018 Край: 30.06.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +18 Merck Sharp & Dohme LLC NCT03742895

Активно (без набиране) Фаза 3

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

Early Breast Cancer

A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).

Начало: 07.12.2018 Край: 29.05.2030 Възраст: 18–100 г. Лечение

Argentina, Australia, Belgium +16 Novartis Pharmaceuticals NCT03701334

Активно (без набиране) Фаза 2/3

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

Prostate Cancer

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

Начало: 26.11.2018 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, China, Denmark +8 Eli Lilly and Company NCT03706365

Активно (без набиране)

Hypofractionated Regional Nodal Irradiation in Breast Cancer

Breast Cancer

This is a prospective clinical trial designed to evaluate the efficacy and safety of hypofractionated regional nodal irradiation in breast cancer patients. After enrollment, participants will be stratified into 2 Groups based on the extent of axillary surgery. Participants will complete activities and assessments at baseline, and after completion of treatment at 1-2 weeks, 3 months, 6 months, 1 year, 2 year, and 3 years following completion of treatment.

Начало: 13.11.2018 Край: 01.07.2027 Възраст: от 18 г.

United States Corewell Health East NCT06443359

Активно (без набиране) Фаза 3

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms Muscle-Invasive Bladder Cancer

The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).

Начало: 06.11.2018 Край: 30.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Bristol-Myers Squibb NCT03661320

Активно (без набиране) Фаза 2

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).

Начало: 10.10.2018 Край: 01.08.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +23 AbbVie NCT03539536

Активно (без набиране) Фаза 3

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Differentiated Thyroid Cancer

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.

Начало: 05.10.2018 Край: 31.07.2026 Възраст: от 16 г. Лечение

Argentina, Australia, Belgium +21 Exelixis NCT03690388

1 … 80 81 82 83 84 … 100